QTc interval screening for cardiac risk in methadone treatment of opioid dependence

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Pani, Pier Paolo ^a   Trogu, Emanuela ^a   Maremmani, Icro ^b   Pacini, Matteo ^c  

^a Territorial Department of Nephrology and Dialysis   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NARCOTIC AGENT;

CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; HUMAN; MORBIDITY; MORTALITY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; QTC INTERVAL; REVIEW; SCREENING TEST; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; OPIOID-RELATED DISORDERS; TORSADE DES POINTES;

HUMANS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; TORSADES DE POINTES;

EID: 84890372544     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008939.pub2     Document Type: Review

References (83)

1. Fareed A, Vayalapalli S, Byrd-Sellers J, Casarella J, Drexler K, Amar R, et al.Onsite QTc interval screening for patients in methadone maintenance treatment. Journal of Addictive Diseases 2010;29:15-22.
2. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?. Drug and Alcohol Review 2011;30:388-96.
3. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009;104:993-9.
4. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H. Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug and Alcohol Dependence 2010;112:216-9.
5. Ansermot N, Albayrak Ö, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, et al.Substitution of (R, S)-methadone by (R)-methadone impact on QTc interval. Archives of Internal Medicine 2010;170:529-36.
6. Bargagli AM, Hickman M, Davoli M, Perucci CA, Schifano P, Buster M, et al.COSMO European Group. Drug-related mortality and its impact on adult mortality in eight European countries. European Journal of Public Health 2006;16:198-202.
7. Bart G. CSAT's QT interval screening in methadone report: outrageous fortune or sea of troubles?. Journal of Addictive Diseases 2011;30:313-7.
8. Bartu A, Freeman NC, Gawthorne GS, Codde JP, Holman CD. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction 2004;99:53-60.
9. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with non antiarrhythmic drugs and observations on gender and QTc. American Journal of Cardiology 2002;89:1316-9.
10. Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. Addiction 2010;105:1531-7.
11. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, García de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005;100:981-9.
12. Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002;97:993-1001.
13. Byrne A. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Annals of Internal Medicine 2009;151:216.
14. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. Substance Use and Misuse 1996;31:177-96.
15. Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief United States, 1999-2010. MMWR CDC Morbidity and Mortality Weekly Report 2012;61:493-7.
16. Cerdá M, Ransome Y, Keyes KM, Koenen KC, Tracy M, Tardiff KJ, et al.Prescription opioid mortality trends in New York City, 1990-2006: examining the emergence of an epidemic. Drug and Alcohol Dependence 2013 [Epub ahead of print]. [DOI: 10.1016/j.drugalcdep.2012.12.027]
17. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. American Journal of Medicine 2008;121:66-71.
18. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug and Alcohol Dependence 2008;94:151-7.
19. Cohen SP, Mao J. Concerns about consensus guidelines for QTc interval screening in methadone treatment. Annals of Internal Medicine 2009;151:216-7.
20. Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Human Psychopharmacology 2004;19:565-76.
21. Daley DC, Marlatt GA. Relapse prevention: cognitive and behavioral interventions. In: Lowinson JH, Ruiz P, Millman BR, Langrod JC editor(s). Substance Abuse, A Comprehensive Textbook. Baltimore: Williams & Wilkins, 1993:533-42.
22. Darke S, Hall W. Heroin overdose: research and evidence based intervention. Journal of Urban Health 2003;80:189-200.
23. Dasgupta N, Bailey EJ, Cicero T, Inciardi J, Parrino M, Rosenblum A, et al.Postmarketing surveillance of methadone and buprenorphine in the United States. Pain Medicine 2010;11:1078-91.
24. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, et al.VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102:1954-9.
25. De Bels D, Staroukine M, Devriendt J. Torsades de pointes due to methadone. Annals of Internal Medicine 2003;139:E156.
26. de Jong IM, de Ruiter GS. Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: a case report. Netherlands Heart Journal 2013;21:249-252.
27. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Safety 2002;25:263-86.
28. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug and Alcohol Dependence 2009;105:9-15.
29. Eap CB, Crettol S, Rougier JS, Schlapfer J, SintraGrilo L, Deglon JJ. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical Pharmacology and Therapeutics 2007;81:719-28.
30. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al.Drug induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalised patients and risk factors. Archives of Internal Medicine 2006;166:1280-7.
31. Elming H, Brendorp B, Køber L, Sahebzadah N, Torp-Petersen C. QTc interval in the assessment of cardiac risk. Cardiac Electrophysiology Review 2002;6:289-94.
32. Cochrane Effective Practice and Organisation of Care (EPOC) Group. Draft EPOC 'Risk of Bias' guideline. http://www.epoc.cochrane.org/en/handsearchers.html. John Wiley and Sons, 2009.
33. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002208]
34. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Hearth 2007;93:1051-5.
35. Food, Drug Administration. FDA ALERT: death, narcotic overdose, and serious cardiac arrhythmias, 2006. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142841.htm accessed May 2013.
36. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clinical Infectious Diseases 2006;43:S173-7.
37. Florian J, Garnett CE, Nallani SC, Rappaport BA, Throckmorton DC. A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clinical Pharmacology & Therapeutics 2012;91:666-72.
38. Fonseca F, Marti-Almor J, Pastor A, Cladellas M, Farré M, de la Torre R, et al.Prevalence of long QTc interval in methadone maintenance patients. Drug and Alcohol Dependence 2009;99:327-32.
39. Fredheim OM, Borchgrevink PC, Hegrenaes L, Kaasa S, Dale O, Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. Journal of Pain Symptom Management 2006;32:180-5.
40. Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz E. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades - 1969-1998. Pharmacoepidemiology and Drug Safety 2000;9 Suppl 1:S24.
41. Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, et al.QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. American Journal of Cardiology 2003;92:995-7.
42. Gourevitch MN. First do no harm. reduction?. Annals of Internal Medicine 2009;150:417-8.
43. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004145]
44. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-4.
45. Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. Journal of Interventional Cardiac Electrophysiology 2010;28:19-22.
46. Hickman M, Carnwath Z, Madden P, Farrell M, Rooney C, Ashcroft R, et al.Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. Journal of Urban Health 2003;80:274-87.
47. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
48. Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction 2006;101:1333-8.
49. Justo D. Methadone-induced long QT syndrome vs methadone-induced torsades de pointes. Archives of Internal Medicine 2006;166:2288.
50. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, et al.QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.
51. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Annales of Internal Medicine 2002;137:501-4.
52. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsades de pointes. Pharmacotherapy 2003;23:802-5.
53. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacotherapy 2005;25:1523-9.
54. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005;25:611-14.
55. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Annales of Internal Medicine 2009;150:387-95.
56. Law M. Screening without evidence of efficacy. BMJ 2004;328:301-2.
57. Madden ME, Shapiro SL. The methadone epidemic: methadone-related deaths on the rise in Vermont. The American Journal of Forensic Medicine and Pathology 2011;32:131-5.
58. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. European Addiction Research 2005;11:44-9.
59. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. American Journal of Cardiology 2005;95:915-8.
60. Martin JA, Campbell A, Killip T, Kotz M, Krantz MJ, Kreek MJ, et al.QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel. Journal of Addictive Diseases 2011;30:283-306.
61. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD002207]
62. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association 2000;284:1689-95.
63. Methadone Maintenance Treatment Program Standards and Clinical Guidelines. College of Physicians & Surgeons of Ontario, Totonto, Ontario,. 4th 2011.
64. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Archives of Internal Medicine 2004;164:943-8.
65. Nichol G, Thomas E, Callaway CW, Hedges J, Powell JL, Aufderheide TP, et al.Resuscitation Outcomes Consortium Investigators. Regional variation in out-of-hospital cardiac arrest incidence and outcome. Journal of the American Medical Association 2008;300:1423-31.
66. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses, 2008. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm, accessed May 2013.
67. Patel AM, Singh JP, Ruskin JN. Role of implantable cardioverter-defibrillators in patients with methadone-induced long QT syndrome. American Journal of Cardiology 2008;101:209-11.
68. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiology and Drug Safety 2005;14:747-53.
69. Pedersen HS, Elming H, Seibaek M, Burchardt H, Brendorp B, Torp-Pedersen C, et al.DIAMOND Study Group. Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving dofetilide. American Journal of Cardiology 2007;100:876-80.
70. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007;102:289-300.
71. Pilgrim JL, McDonough M, Drummer OH. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. Forensic Science International 2013;226:216-22.
72. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al.Risk stratification in the long-QT syndrome. New England Journal of Medicine 2003;348:1866-74.
73. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al.Relationships between preclinical cardiac electrophysiology, clinical QTinterval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research 2003;58:32-45.
74. Seyler DE, Borowitz JL, Maickel RP. Calcium channel blockade by certain opioids. Fundamental and Applied Toxicology 1983;3:536-42.
75. Sims SA, Snow LA, Porucznik CA. Surveillance of methadone-related adverse drug events using multiple public health data sources. Journal of Biomedical Informatics 2007;40:382-9.
76. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. American Journal of Cardiology 1990;65 Suppl:74A-81A.
77. Sporer KA. Acute heroin overdose. Annals of Internal Medicine 1999;130:584-90.
78. Thanavaro KL, Thanavaro JL. Methadone-induced torsades de pointes: a twist of fate. Heart Lung 2011;40:448-53.
79. Drug Misuse and Dependence: UK Guidelines on Clinical Management. Department of Health (England), the Scottish Government, Welsh Assembly Government, and Northern Ireland Executive, 2007.
80. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et ak. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005;2:569-74.
81. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomised trial. Archives of Internal Medicine 2007;167:2469-75.
82. WHO. The methadone fix. Bulletin of the World Health Organization 2008;86:164-5.
83. Wolff K. Characterization of methadone overdose: clinical considerations and the scientific evidence. Therapeutic Drug Monitoring 2002;24:457-70.